Group 1: Guizhou Moutai - Guizhou Moutai reported a net profit of 646.27 billion yuan for the first three quarters of 2025, an increase of 6.25% year-on-year [1][2] - The company's revenue for the first three quarters reached 1,284.54 billion yuan, reflecting a growth of 6.36% compared to the previous year [1][2] Group 2: Midea Group - Midea Group achieved a net profit of 378.83 billion yuan for the first three quarters of 2025, marking a year-on-year increase of 19.51% [3][4] - The company's revenue for the same period was 3,630.57 billion yuan, up 13.82% year-on-year [3][4] Group 3: Mindray Medical - Mindray Medical reported a net profit of 75.7 billion yuan for the first three quarters of 2025, a decline of 28.83% year-on-year [5][6] - The company's revenue for the first three quarters was 258.34 billion yuan, down 12.38% compared to the previous year [5][6] Group 4: SanHuan Group - SanHuan Group's net profit for the first three quarters of 2025 was 19.59 billion yuan, reflecting a growth of 22.16% year-on-year [7][8] - The company's revenue for the same period reached 65.08 billion yuan, an increase of 20.96% year-on-year [7][8] Group 5: Longyuan Power - Longyuan Power reported a net profit of 43.93 billion yuan for the first three quarters of 2025, a decrease of 21.02% year-on-year [9][10] - The company's revenue for the same period was 222.21 billion yuan, down 17.29% compared to the previous year [9][10] Group 6: China Nuclear Power - China Nuclear Power's net profit for the first three quarters of 2025 was 80.02 billion yuan, a decline of 10.42% year-on-year [12][13] - The company's revenue for the same period reached 616.35 billion yuan, an increase of 8.16% year-on-year [12][13] Group 7: Fenjie Media - Fenjie Media reported a net profit of 42.40 billion yuan for the first three quarters of 2025, an increase of 6.87% year-on-year [14][15] - The company's revenue for the same period was 96.07 billion yuan, reflecting a growth of 3.73% year-on-year [14][15] Group 8: Tianfu Communication - Tianfu Communication achieved a net profit of 14.65 billion yuan for the first three quarters of 2025, marking a year-on-year increase of 50.07% [17][18] - The company's revenue for the same period was 39.18 billion yuan, up 63.63% year-on-year [17][18] Group 9: Lingyi Technology - Lingyi Technology reported a net profit of 19.41 billion yuan for the first three quarters of 2025, reflecting a growth of 37.66% year-on-year [19][20] - The company's revenue for the same period reached 375.90 billion yuan, an increase of 19.25% year-on-year [19][20] Group 10: Rongsheng Petrochemical - Rongsheng Petrochemical's net profit for the first three quarters of 2025 was 8.88 billion yuan, a growth of 1.34% year-on-year [21] - The company's revenue for the same period was 2,278.15 billion yuan, down 7.09% compared to the previous year [21] Group 11: ShenNan Circuit - ShenNan Circuit reported a net profit of 23.26 billion yuan for the first three quarters of 2025, an increase of 56.30% year-on-year [22] - The company's revenue for the same period was 167.54 billion yuan, reflecting a growth of 28.39% year-on-year [22] Group 12: Jiangbolong - Jiangbolong achieved a net profit of 7.13 billion yuan for the first three quarters of 2025, marking a year-on-year increase of 27.95% [23] - The company's revenue for the same period reached 167.34 billion yuan, up 26.12% year-on-year [23] Group 13: New Yisheng - New Yisheng reported a net profit of 63.27 billion yuan for the first three quarters of 2025, reflecting a growth of 284.37% year-on-year [24] - The company's revenue for the same period was 165.05 billion yuan, an increase of 221.70% year-on-year [24] Group 14: China Merchants Bank - China Merchants Bank achieved a net profit of 1,137.72 billion yuan for the first three quarters of 2025, marking a year-on-year increase of 0.52% [25] - The company's revenue for the same period was 2,514.2 billion yuan, down 0.51% compared to the previous year [25] Group 15: Zhongwei Company - Zhongwei Company reported a net profit of 12.11 billion yuan for the first three quarters of 2025, a growth of approximately 32.66% year-on-year [26] - The company's revenue for the same period reached 80.63 billion yuan, an increase of approximately 46.40% year-on-year [26] Group 16: Microchip Biotech - Microchip Biotech's non-public offering was approved, aiming to raise up to 9.5 billion yuan for innovative drug research and development [27] Group 17: Longyuan Power's Fundraising - Longyuan Power plans to raise up to 50 billion yuan through a private placement to invest in renewable energy projects [28] Group 18: North University Pharmaceutical - North University Pharmaceutical's chairman was detained for investigation, but the company's operations remain normal [29] Group 19: Deyang Shares - Deyang Shares reported a net profit of 23.47 billion yuan for the first three quarters of 2025, a growth of 4.79% year-on-year [30] Group 20: Xiechuang Data - Xiechuang Data achieved a net profit of 6.98 billion yuan for the first three quarters of 2025, marking a year-on-year increase of 25.30% [31] Group 21: Zhifei Biological - Zhifei Biological reported a net loss of 12.06 billion yuan for the first three quarters of 2025, primarily due to lower sales and increased provisions [32] Group 22: Softcom Power - Softcom Power achieved a net profit of 9.89 billion yuan for the first three quarters of 2025, reflecting a growth of 30.21% year-on-year [33] Group 23: Magmi Technology - Magmi Technology reported a net profit of 2.13 billion yuan for the first three quarters of 2025, a decline of 48.29% year-on-year [34] Group 24: Huali Group - Huali Group's net profit for the first three quarters of 2025 was 24.35 billion yuan, a decrease of 14.34% year-on-year [35]

Core Insights - The company reported a significant decline in revenue and a net loss for the first three quarters of 2025, indicating a challenging market environment [1] Financial Performance - The company achieved an operating revenue of 7.627 billion yuan, representing a year-on-year decrease of 66.53% [1] - The net profit attributable to shareholders was -1.206 billion yuan, marking a shift from profit to loss compared to the previous year [1] Reasons for Revenue Decline - The company attributed the decrease in revenue to underperformance in market sales, which did not meet expectations [1]

Core Viewpoint - Zhifei Biological's Q3 2025 report shows a continuous recovery in operating income, indicating a positive trend in the company's financial health and operational performance [1][3]. Financial Performance - In Q3 2025, Zhifei Biological achieved operating income of 2.705 billion yuan, a 6.29% increase from Q2, marking two consecutive quarters of positive growth [3]. - The net cash flow from operating activities reached 2.985 billion yuan, a year-on-year increase of 201.18%, maintaining positive cash flow for three consecutive reporting periods [3]. - Accounts receivable and inventory decreased by 5.21% and 9.85% year-on-year, respectively, reflecting improved operational efficiency [3]. Product Development and Market Expansion - The company is expanding its product portfolio with multiple self-developed products and has received approvals for new indications for its exclusive agency products, including the four-valent and nine-valent HPV vaccines for males [3][4]. - The restructured shingles vaccine has also been approved for new target groups, significantly increasing its market potential, especially given the high burden of shingles in China [4]. - Zhifei Biological has 34 self-developed projects, with 21 in various stages of clinical trials and regulatory submissions, indicating a robust pipeline for future growth [4][5]. Strategic Initiatives - The company is optimizing its marketing strategies and inventory turnover, contributing to a stabilization in revenue [3]. - Zhifei Biological is enhancing its integrated "prevention & treatment" approach through its subsidiary, aiming to leverage advancements in GLP-1 class drugs for weight loss and diabetes management [5]. - The company is actively pursuing global market opportunities, focusing on high-quality innovative products to expand its international presence [5][6].

Core Viewpoint - Zhifei Biological (300122) announced the election of Mr. Yang Shilong as the sixth employee representative director during the employee representative assembly held on October 28, 2025 [1] Group 1 - The employee representative assembly was held on October 28, 2025 [1] - Mr. Yang Shilong was elected as the employee representative director [1]

证券代码：300122 证券简称：智飞生物 公告编号：2025-62 重庆智飞生物制品股份有限公司 关于公司员工持股计划（2022 年）存续期展期的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第六届董事会第八次会议，审议通过了《关于公司员工持股计划（2022 年）存续期展期的议案》，同意公司员工持股计划（以下简称"本员工持股计划"） 存续期展期 24 个月，即展期至 2028 年 3 月 10 日。现将相关情况公告如下： 特此公告 重庆智飞生物制品股份有限公司董事会 公司于 2022 年 1 月 28 日召开第五届董事会第四次会议和第五届监事会第三 次会议，于 2022 年 2 月 14 日召开 2022 年第一次临时股东大会，审议通过了《关 于〈公司共同富裕之员工持股计划草案（2022 年）〉及其摘要的议案》《关于 〈公司共同富裕之员工持股计划（2022 年）管理办法〉的议案》等相关议案， 同意公司实施本员工持股计划。公司委托上海迎水投资管理有限公司对员工持股 ...

证券代码：300122 证券简称：智飞生物 公告编号：2025-64 重庆智飞生物制品股份有限公司 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》和《上市公司 章程指引》等有关法律法规和规范性文件的规定，重庆智飞生物制品股份有限公 司（以下简称"公司"）拟修订《公司章程》，取消监事会，原监事会的职权由 董事会审计委员会承接，同时设置职工代表董事。 董事会于近日收到董事杨世龙先生提交的书面辞职报告。因公司治理结构及 内部工作调整，杨世龙先生申请辞去公司第六届董事会董事职务，同时辞去董事 会战略与可持续发展委员会委员职务。辞任后杨世龙先生将继续担任公司其他职 务。杨世龙先生的辞任不会导致公司董事会人数低于法定最低人数，其辞职报告 自送达公司董事会之日起生效。 公司于 2025 年 10 月 28 日召开了职工代表大会，经过民主讨论、表决，选 举杨世龙先生为公司第六届职工代表董事（简历详见附件）。杨世龙先生任 ...

重庆智飞生物制品股份有限公司 关于召开2025年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 证券代码:300122 证券简称:智飞生物 公告编号:2025-65 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— 创业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公 司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 18 日 9:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2025 年 11 月 18 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为 2025 年 11 月 18 日 9:15 至 15:00 的 任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：202 ...

证券代码：300122 证券简称：智飞生物 公告编号：2025-60 重庆智飞生物制品股份有限公司 第六届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会于 2025 年 10 月 21 日以电子邮件的方式向监事发出通知。 2、本次会议于 2025 年 10 月 28 日 11:00 在公司会议室以现场结合通讯方式 召开。 3、本次会议应出席并参加表决的监事 3 人，实际出席并参加表决的监事 3 人。 4、本次会议由公司监事会主席荀婕女士主持。 5、本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和公司章程的规定。 经审核，监事会认为：董事会编制和审核公司 2025 年第三季度报告的程序 符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了 公司的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 具体内容详见当日发布在中国证监会指定信息披露网站巨潮资讯网的公司 《2025 年第三季度报告》（2025-61）。 表决结果：赞成 3 票，反对 0 票， ...

证券代码：300122 证券简称：智飞生物 公告编号：2025-59 重庆智飞生物制品股份有限公司 第六届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 3、本次会议应出席并参加表决的董事 9 人，实际出席并参加表决的董事 9 人。 4、本次会议由公司董事长蒋仁生先生主持，公司高级管理人员列席了本次 会议。 5、本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件及公司章程的规定。 二、董事会会议审议情况 经过各位董事认真审议，本次会议形成如下决议： 1、审议通过了《2025 年第三季度报告》 公司《2025 年第三季度报告》的编制程序符合法律、法规和中国证监会的 有关规定，报告内容真实、准确、完整地反映了公司的实际经营情况。 具体内容详见当日发布在中国证监会指定信息披露网站巨潮资讯网的公司 《2025 年第三季度报告》（2025-61）。 本议案已经公司董事会审计委员会审议通过，全体委员表示一致同意。 表决结果：赞成 9 票，反对 0 票，弃权 0 票，本议案获得通过。 1、本次董事会 ...

(本文来自第一财经) 智飞生物公告，2025年第三季度营业收入为27.05亿元，同比下降40.26%；归属于上市公司股东的净利 润亏损6.01亿元。前三季度实现营业收入76.27亿元，同比下降66.53%；归属于上市公司股东的净利润 亏损12.06亿元。 ...